Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-07-31
2009-10-20
Allen, Marianne P (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S399000
Reexamination Certificate
active
07605122
ABSTRACT:
The present invention relates to formulations of hCG for sublingual administration to mammals to facilitate weight loss and/or body contouring. Embodiments of the invention disclose administration of hCG formulations in combination with a low calorie diet and dietary supplements and, in some cases, with an exercise regime. Embodiments of this invention also disclose transdermal hCG formulations and hCG formulations for administration through other administration routes.
REFERENCES:
patent: 5514670 (1996-05-01), Friedman et al.
patent: 5610136 (1997-03-01), McMichael
patent: 6284262 (2001-09-01), Place
patent: 6416740 (2002-07-01), Unger
patent: 6720001 (2004-04-01), Chen et al.
patent: 7101847 (2006-09-01), McMichael
patent: 2005/0096264 (2005-05-01), MacDonald et al.
patent: 2006/0041058 (2006-02-01), Yin et al.
patent: 2006/0063713 (2006-03-01), Yoon
patent: 2008/0249302 (2008-10-01), Maddaford et al.
“Effect of human chorionic gonadotrophin on weight loss, hunger, and feeling of well-being,” W.L. Asher, M.D., and Harold W. Harper, M.D.; The American Journal of Clinical Nutrition 26: Feb. 1973, pp. 211-218.
“Controversies in Plastic Surgery: Suction-Assisted Lipectomy (SAL) and the hCG (Human Chorionic Gonadotropin) Protocol for Obesity Treatement,” Trudy Vogt, M.D., and Daniel Belluscio, M.D., Aesthetic Plastic Surgery, 11:131-156, 1987.
“El Uso de la Gonadotrofina Corionica Humana (hCG) por via Oral Para el Tratamiento de la Obesidad: Estudio A Doble Ciego,” Daniel O. Belluscio, M.D., and Leonor E. Ripamonte, M.D.; Rev. Inst. Med. “Sucre” LXIV: 115 (14-21) 1999.
“The Action of Chorionic Gonadotrophin in the Obese,” A.T.W. Simeons, M.D. Heidelberg; The Lancet, Nov. 6, 1954, pp. 946-947.
Albrink, M.J.,Chorionic gonadotropin and obesity?, Am J Olin Nutr, Jun. 1969, vol. 22, No. 6, pp. 681-685.
Greenway, et al.,Human chorionic gonadotropin(HCG)in the treatment of obesity: a critical assessment of the Simeons method, West J. Med, Dec. 1977, vol. 127, No. 6, pp. 461-463.
Gusman,Chorionic gonadotropin in obesity. Further clinical observations, Am J Olin Nutr, Jun. 1969, vol. 22, No. 6, pp. 686-695.
Stein, et al.,Ineffectiveness of human chorionic gonadotropin in weight reduction: a double-blind study, Am J. Clin Nutr., Sep. 1976, vol. 29, No. 9, pp. 940-948.
Veilleux, et al.,Gonadic and extragonadic effects in humans of 3,500 I.U. of HCG(human chorionic gonadotropin)in fractional doses, Vie Med Can Fr., Sep. 1972, vol. 1, No. 9, pp. 862-871.
Boyer,L'hCG dans l'obésité: non, non et non!, Med Quebec, Jun. 1976, pp. 81-82.
Craig, et al.,Chorionic gonadotropin in the treatment of obese women, Am J Clin Nutr, Mar. 1963, vol. 12, pp. 230-234.
Felig, et al.,Metabolic response to hGH during prolonged fasting, J Clin Invest, 1971, vol. 50, pp. 411-421.
Frank,The use of chorionic gonadotropin hormone in the treatment of obesity, Am J Olin Hutr, 1964, vol. 14, pp. 133-136.
Berger, et al.,Is hCG therapy obesity warranted?, Review, German, Aug. 1980, vol. 75, No. 17, pp. 624-625.
Bradley,Human chorionic gonadotropin in weight reduction, (letter), Am J Clin Nutr, May 1977, vol. 30, No. 5, pp. 649-654.
Hutton,Chorionic gonadotropin and obesity, Am J Clin Nutr, Mar. 1970, vol. 23, No. 3, pp. 243-244.
Birmingham, et al.,Human chorionic gonadotropin is of no value in the management of obesity, Can Med Assoc J, May 15, 1983, vol. 128, pp. 1156-1157.
Ballin JC, White PL; Fallacy and hazard; Human chorionic gonadotropin-500-calorie diet and weight reduction; JAMA Nov. 4, 1974; 230 (5): 693-4.
Bosch B., et al., Human chorionic gonadotrophin and weight loss; A double-blind, placebo-controlled trial; S Afr Med J; Feb. 17, 1990; 77(4): 185-9.
Cairella M., Drug therapy of obesity; Clin Ter.; Mar 31, 1978; 84(6): 571-92.
Miller R., et al.; A clinical study of the use of human chorionic gonadotropin in weight reduction, J Fam Pract., Mar. 4, 1977(3): 445-8.
Rivlin RS, Therapy of obesity with hormones; N. Engl J Med; Jan 2, 1975; 292(1): 26-9.
Shetty KR, et al.; Human chorionic gonadotropin (HCG) treatment of obesity; Arch Intern Med., Feb. 1977; 137(2): 151-5.
Yanagihara Y.; Carbohydrate and lipid metabolism in pregnant albino rats during hunger after loading with gonad-stimulating hormones; Nippon Sanka Jujinka Gakkal Xasshi; Nov. 1966; 18(11): 1293-301.
Yanagihara Y.; Carbohydrate and fatty acid metabolism in pregnant albino rats simultaneously loaded with fat emulsion and sex stimulating hormones during stqarvation; Nippon Sanka Jujinka Gakkai Zasshi, Jan. 1967; 19(1): 8-14.
Yanagihara Y.; Carbohydrate and lipid metabolism in pregnant albino rats during starvation after loading with gonad-stimulating hormones; Nippon Sanka Fukinka Gakkal Zasshi, Dec. 1966; 18(12): 1379-84.
Young RL., et al., Chorionic gonadotropin in weight control. A double-blind crossover study; JAMA Nov. 29, 1976; 236(22): 2495-7.
Cargille CM: Human chorionic gonadotropin not indicated for obesity; J Am Med Assoc; 219(11): 1485-1486, 1972.
Carne S: The action of chorionic gonadotropin in the obese; Lancel II: 1282-1284, 1961.
Dunn CE: Human chorionic gonadotropin for weight reduction; Am J Obstet Gynecol; 120: 855, 1974.
Hastrup B. Nielsen B., Skouby AP: Chorionic gonadotropin and the treatment of obesity; Acta Med Scand 168(1): 25-27, 1960.
Perelberg H: Chorionic gonadotrophin (HCG) and obesity; Med J Austr 64(2): 68-69, 1977.
Bradley P; Chorionic gonadotrophin (HCG) and obesity; Med J. Aust; 22; 2(17): 581; Oct. 1977.
Bradley P; The equilibrium set-point weight; human chorionic gonadotrophin and obesity; In J. Obes. 3(4): 380-389; 1979.
Faludi G.; Use of chorionic gonadotropin in obesity; Am Fam Physician; 11(5): 156-157; May 1975.
Hutton JH, et al.; Human chorionic gonadotropin (hCG) in treatment of obesity, IMJ III Med. J; 132(5): 693-695; Nov. 1967.
Maudlin RK; Gonadotropins in obesity? Am Fam Physician; 8(4): 202-203; Oct. 1973.
Rath R., et al.; Use of choriogonadotropin in the treatment of obesity; Vnitr Leic 20(7): 681-685 Czech; Jul. 1974.
Vallini A., et al.; Treatment of obesity with chorionic gonadotropin. Relations between obesity, dyslipidemia and arthero-arteriosclerosis; Minerva Med; 7; 67(33): 2113-2132, Italian; Jul. 1976.
Simeons, M.D., Salvator Mundi International Hospital, Rome, Italy; Chorionic Gonadotropin In Geriatrics; Journal of the American Geriatrics Society, vol. IV, Jan. 1956 No. 1.
Sohar, “A Forty-Day-550 Calorie Diet in the Treatment of Obese Outpatients,” American Journal of Clinical Nutrition, 7:514-518 (Sep.-Oct. 1959).
Allen Marianne P
DeBerry Regina M
Knobbe Martens Olson & Bear LLP
Millennium Medical Spa
LandOfFree
Human chorionic gonadotropin (hCG) formulations for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human chorionic gonadotropin (hCG) formulations for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human chorionic gonadotropin (hCG) formulations for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4101747